Changes in vision related quality of life in patients with diabetic macular edema: Ranibizumab or laser treatment?

Patient-reported outcomes and visual acuity after 12 months of anti-VEGF-treatment for sight-threatening diabetic macular edema in a real world setting

“…Approximately 50% of the patients improved their visual acuity after 4 months and remains at 12 months, which is consistent with other studies [15,33,42]. The general health measured with NEI VFQ-25 improved from baseline as seen in other studies [15,34], although there were low scores for baseline values [23]. The total sample population had significantly improved ETDRS scores and OCT results.…”

“…Anti-VEGF treatment is capable of improving vision instead of merely stabilizing the condition [28,29]. Several studies have reported that ranibizumab improves patient-reported visual function [15,[30][31][32][33][34], which can be stabilized for long periods of time [17].…”

Development and validation of the canine visual function instrument

“…Quality of life questionnaires have been used extensively to study effects of treatments in a variety of human ocular disease. In one study, a questionnaire was utilized to assess effectiveness of ranibizumab compared to laser for treatment of diabetic macular edema . Another study compared posterior chamber phakic intraocular lens implantation to keratomileusis for treatment of myopia utilizing a vision‐related quality of life survey to determine that posterior chamber IOLs provided significant vision‐related quality of life advantages .…”

How to prevent the microvascular complications of type 2 diabetes beyond glucose control

“…62 Participants were randomly allocated to focal/grid laser or intravitreal ranibizumab applied to the better seeing eye. Baseline retinal parameters were similar in the two groups.…”